Hormone Replacement Therapy

Combined therapy with SERMs and estrogen show promise in rat studies

Published in Drug Week, November 28th, 2003

Doctors at Laval University in Quebec, Canada, report that EM-652, a selective estrogen receptor modulator (SERM) given in association with an estrogen, may be effective for controlling hot flashes and preventing breast, uterine, and ovarian cancers, as well as osteoporosis, in postmenopausal women.

Additionally, the combination shows promise in potentially helping with brain function and preventing Alzheimer's disease with no risk or negative effect.

Their study, published in the November 5, 2003, issue of the journal Endocrinology, discusses this possible safe, future treatment for postmenopausal women.

The results of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry